This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

REGISTER BY FEBRUARY 10 FOR EARLY EVENT PLATFORM ACCESS

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
February 27 - March 2, 2023 | Part of BPI West
San Diego Convention CenterSan Diego, CA

Daniel Shelly, PhD
Vice President Business Development and Alliances at Prescient Therapeutics

Profile

Daniel Shelly, Ph.D., MBA is Vice President of Business Development and Alliances at Prescient Therapeutics where he is responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience. He is also an adjunct professor in the Masters in Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.

Agenda Sessions

  • Multi-Antigen Targeting and Redirection with a Novel Universal Immune Receptor

    11:00am